Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
AssigneeUniversity of Massachusetts
InventorsJaime Antonio Rivera-Perez, Guangping Gao
Life of this patent
Estimating the term…
Abstract
The disclosure, in some aspects, relates to methods and compositions for recombinant adeno-associated virus (rAAV)-mediated delivery of genome editing molecules to a pre-implantation embryo.
Claims11
A method for delivering a gene editing molecule to cells of a pre-implantation embryo comprising an intact zona pellucida, the method comprising transducing the pre-implantation embryo in an oviduct of a subject with a recombinant adeno-associated virus (rAAV) having a capsid harboring a nucleic acid comprising a promoter operably linked to a transgene encoding a gene editing molecule, wherein the transducing does not comprise injection of the rAAVs into the pre-implantation embryo, and wherein the transducing comprises direct injection of the rAAV into the oviduct of the subject.
A method for facilitating genome editing in cells of a pre-implantation embryo comprising an intact zona pellucida, the method comprising transducing the pre-implantation embryo in an oviduct of a subject with:
- a first rAAV comprising a capsid harboring a nucleic acid comprising a promoter operably linked to a transgene encoding a guide RNA;
- and
- a second rAAV comprising a capsid harboring a nucleic acid comprising a promoter operably linked to a transgene encoding a CRISPR/Cas-associated protein,
- wherein the transducing does not comprise injection of the first rAAV and second rAAVs into the pre-implantation embryo, and wherein the transducing comprises direct injection of the first and second rAAVs into the oviduct of the subject.
Dependencies are inferred from the claim text.